MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
67.7 M |
Market Cap[1] |
$ 4.57 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
ММЦБ
GEMA
|
- | - | - | MOEX | Russia |
 |
Lyra Therapeutics
LYRA
|
- | - | $ 24.9 M | Nasdaq Global Market | USA |
 |
ОЗОН Фармацевтика
OZPH
|
- | - | - | MOEX | Russia |
 |
Промомед
PRMD
|
- | - | - | MOEX | Russia |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
ESSA Pharma
EPIX
|
- | - | $ 8.86 M | Nasdaq Capital Market |  Canada |
 |
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | USA |
 |
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | USA |
 |
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market |  Niderland |
 |
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | USA |
 |
Annexon
ANNX
|
$ 4.0 | -7.62 % | $ 620 M | Nasdaq Global Select Market | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 156.5 | -2.85 % | $ 20.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Amgen
AMGN
|
$ 462.71 | -3.3 % | $ 249 B | Nasdaq Global Select Market,SPB | USA |
 |
Theratechnologies
THTX
|
- | - | $ 83.9 M | Nasdaq Capital Market | Canada |
 |
Iovance Biotherapeutics
IOVA
|
$ 7.72 | -11.26 % | $ 2.76 M | Nasdaq Global Market,SPB | USA |
 |
Biogen
BIIB
|
$ 243.85 | -4.17 % | $ 35.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
$ 4.03 | 6.9 % | $ 652 M | Nasdaq Global Select Market | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.01 | -4.14 % | $ 109 M | NYSE American | USA |
 |
Mustang Bio
MBIO
|
$ 0.39 | -5.63 % | $ 1.91 M | Nasdaq Global Market | USA |
 |
MannKind Corporation
MNKD
|
$ 3.77 | -4.07 % | $ 1.15 B | Nasdaq Global Market | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.36 | -8.11 % | $ 91.5 M | Nasdaq Global Select Market |  Germany |
 |
Immutep Limited
IMMP
|
$ 2.7 | -8.47 % | $ 3.93 B | Nasdaq Global Market |  Australia |
 |
Insmed Incorporated
INSM
|
$ 108.79 | -1.1 % | $ 21.7 B | Nasdaq Global Select Market | USA |
 |
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | Nasdaq Capital Market | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 227.25 | -3.16 % | $ 13.9 B | Nasdaq Global Select Market |  Irlanda |
 |
BioLineRx Ltd.
BLRX
|
$ 1.77 | -4.95 % | $ 4.36 B | Nasdaq Capital Market |  Israel |
 |
Bristol-Myers Squibb Company
BMY
|
$ 63.15 | -1.64 % | $ 128 B | NYSE,SPB | USA |
 |
Johnson & Johnson
JNJ
|
$ 272.47 | -1.4 % | $ 656 B | NYSE,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
PainReform Ltd.
PRFX
|
$ 0.76 | -1.27 % | $ 492 K | Nasdaq Capital Market | Israel |
 |
Kala Pharmaceuticals
KALA
|
$ 0.15 | -13.14 % | $ 1.22 M | Nasdaq Global Select Market | USA |
 |
Prothena Corporation plc
PRTA
|
$ 7.9 | -5.84 % | $ 425 M | Nasdaq Global Select Market,SPB | USA |
 |
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
$ 14.53 | -1.63 % | $ 12.1 B | NYSE |  India |
 |
Keros Therapeutics
KROS
|
$ 9.42 | -13.02 % | $ 351 M | Nasdaq Global Select Market | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | USA |
 |
Kazia Therapeutics Limited
KZIA
|
$ 7.13 | -11.76 % | $ 109 M | Nasdaq Global Select Market | Australia |
 |
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | Nasdaq Global Select Market | USA |
 |
Sana Biotechnology
SANA
|
$ 2.32 | -9.38 % | $ 588 M | Nasdaq Global Select Market | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 0.98 | -4.85 % | $ 226 M | NYSE American | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
$ 298.8 | -5.48 % | $ 5.78 B | Nasdaq Global Select Market,SPB | USA |
 |
Longeveron
LGVN
|
$ 1.76 | -1.12 % | $ 30.9 B | Nasdaq Global Select Market | USA |
 |
Eli Lilly and Company
LLY
|
$ 1 366.97 | -3.62 % | $ 1.23 T | NYSE,SPB | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | Nasdaq Capital Market | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
$ 4.01 | -5.2 % | $ 48.9 M | Nasdaq Capital Market | Israel |
 |
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | Nasdaq Global Market | USA |
 |
Compugen Ltd.
CGEN
|
$ 1.94 | -4.68 % | $ 181 M | Nasdaq Global Market,SPB | Israel |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.